

*Applications:* Treatment for cardiac failure.

*Advantages:* Therapies that increase heart contractions without affecting blood pressure.

*Development Status:* The technology is currently in the pre-clinical stage of development.

*Market:*

- In the U.S., cardiac failure affects an estimated 5.7 million people and there are approximately 550,000 newly diagnosed cases per year.

- Cardiac failure was estimated to result in direct and indirect costs of \$37.2 billion in the United States in 2009.

- Heart failure is responsible for 11 million physician visits each year, and more hospitalizations than all forms of cancer combined.

*Inventors:* Y. Peng Loh (NICHD) and Bruno Tota (University of Calabria).

*Relevant Publications:* None. Future publications are being contemplated.

*Patent Status:* U.S. Provisional Application No. 61/427,243 filed 27 Dec 2010 (HHS Reference No. E-001-2011/0-US-01).

*Licensing Status:* Available for licensing.

*Licensing Contact:* Jennifer Wong; 301-435-4633; [wongje@mail.nih.gov](mailto:wongje@mail.nih.gov).

*Collaborative Research Opportunity:* The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Section on Cellular Neurobiology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of serpinin and pyroglu-serpinin in treatment of heart failure. Please contact Joseph Conrad at 301-435-3107 or [jmconrad@mail.nih.gov](mailto:jmconrad@mail.nih.gov) for more information.

### **Alpha-Glucosidase Chaperones and Inhibitors for Treatment of Pompe Disease and Type 2 Diabetes**

*Description of Invention:* Scientists at the NIH have discovered small molecules that can act as chaperones and correct the misfolding of mutated alpha-glucosidase enzyme. Pompe disease is caused by deficiency or dysfunction of alpha-glucosidase. The only FDA-approved treatment of Pompe disease is enzyme replacement, which in this case costs approximately \$300,000 per year and elicits an immune reaction in most patients that limits clinical utility.

In addition, scientists at the NIH have discovered small molecule inhibitors of alpha glucosidase enzyme. Alpha glucosidase converts carbohydrates into monosaccharides. Inhibition of this

conversion is useful for type 2 diabetes. Three FDA-approved inhibitors of alpha glucosidase exist but all have low efficacy:side effect ratios.

*Applications:*

- Therapeutic for Pompe disease.
- Therapeutic for type 2 diabetes.

*Advantages:*

- Potentially more affordable and less immunogenic than the current therapeutic for Pompe disease.
- Potentially better efficacy:side effect ratios than existing type 2 diabetes therapeutics.

*Development Status:* Early stage.

*Market:* Pompe disease occurs in 1 in every 40,000 births (<http://www.ninds.nih.gov/disorders/pompe/pompe.htm>).

*Inventors:* Juan J. Marugan, Ehud M. Goldin, Noel T. Southall, Wei Zheng, Jingbo Xiao, Ellen Sidransky, and Omid Motabar (NHGRI).

*Patent Status:* U.S. Provisional Patent Application No. 61/409/697 filed 03 November 2010 (HHS Reference No. E-256-2010/0-US-01).

*Licensing Status:* Available for licensing.

*Licensing Contact:* Steve Standley, PhD; 301-435-4074; [sstand@od.nih.gov](mailto:sstand@od.nih.gov).

### **Mouse IL-12p40 Expressing Cell Line**

*Description of Invention:* The subject invention is a recombinant human 293T cell line that expresses mouse IL-12p40 protein to high levels. IL-12p40 is a subunit of both Interleukin-12 (IL-12) and IL-23; however, it can also be expressed as a monomer (IL-12p40) and as a homodimer (IL-12p80). IL-12p40 is produced mainly by antigen presenting cells such as macrophages, neutrophils, microglia, and dendritic cells in response to pathogens or inflammatory agents. It is an immunostimulatory messenger molecule that can disseminate in the body and signal the presence of a pathogen. The role of IL-12p40 is still being elucidated. This cell line produces and secretes mouse IL-12p40 proteins that have post-translational modifications similar to native IL-12p40 protein, overcoming an issue that is seen with IL-12p40 protein expressed in bacterial, insect, or hamster cells.

*Applications:* Production of mouse IL-12p40 for research applications.

*Advantages:* IL-12p40 protein is expressed in human cell line, so post-translational modifications are similar to native protein.

*Development Status:* *In vitro* data can be provided upon request.

*Market:* Research reagent.

*Inventors:* Nevil J. Singh (NIAID).

*Patent Status:* HHS Reference No. E-247-2010/0—Research Tool. Patent

protection is not being pursued for this technology.

*Licensing Status:* Available for licensing.

*Licensing Contact:* Kevin W. Chang, PhD; 301-435-5018, [changke@mail.nih.gov](mailto:changke@mail.nih.gov).

Dated: May 20, 2011.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2011-13084 Filed 5-25-11; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Initial Review Group; Function, Integration, and Rehabilitation Sciences Subcommittee.

*Date:* June 24, 2011.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites Hotel, 4300 Military Road, Washington, DC 20015.

*Contact Person:* Anne Krey, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301-435-6908, [Ak41o@nih.gov](mailto:Ak41o@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: May 20, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2011-13121 Filed 5-25-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Initial Review Group, Developmental Biology Subcommittee.

*Date:* June 23-24, 2011.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Legacy Hotel and Meeting Center, 1775 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Neelakanta Ravindranath, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B0G, MSC 7510, Bethesda/Rockville, MD 20817, 301-435-6889, [ravindrn@mail.nih.gov](mailto:ravindrn@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: May 20, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2011-13074 Filed 5-25-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel, Pathophysiology of Intellectual and Developmental Disabilities.

*Date:* June 17, 2011.

*Time:* 2 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

*Contact Person:* Neelakanta Ravindranath, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301-496-1485, [ravindm@mail.nih.gov](mailto:ravindm@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: May 20, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2011-13070 Filed 5-25-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group, Digestive Diseases and Nutrition C Subcommittee.

*Date:* June 27-28, 2011.

*Open:* June 27, 2011, 8 a.m. to 8:30 a.m.

*Agenda:* To review procedures and discuss policy.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Closed:* June 27, 2011, 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Closed:* June 28, 2011, 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Robert Wellner, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 706, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, [rw175w@nih.gov](mailto:rw175w@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: May 20, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2011-13069 Filed 5-25-11; 8:45 am]

**BILLING CODE 4140-01-P**